Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Innocan Pharma Announces First Tranche Closing of Private Placement of Units
HERZLIYA, Israel and CALGARY, Alberta, Sept. 23, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan') is pleased to announce that, further to its press release of September 9, 2026, it has…
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BridgeBio Pharma, Inc. (BBIO) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 9:40 AM EDT Thomas Trimarchi - CFO & President Julie Everett - Chief Operating Officer of Skeletal Dysplasias…
XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks
Investors seeking healthcare exposure must decide between the broad diversification of the healthcare sector and a targeted bet on pharmaceutical manufacturers. The State Street Health Care Select Sector SPDR ETF (XLV -0.64%) provides broad…
Duke Street sells UK pharma distributor Kent Pharma to Phoenix Labs
A verification email is on its way to you. Please check your spam or junk folder just in case. If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email:.
HC Wainwright Boosts Earnings Estimates for Innate Pharma
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Stock analysts at HC Wainwright increased their FY2026 EPS estimates for Innate Pharma in a research report issued on Monday, September 21st. HC Wainwright analyst S. Ramakanth now…
Avalyn Pharma (NASDAQ:AVLN) Stock Price Down 9.2% - Here's Why
Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report)'s stock price dropped 9.2% during mid-day trading on Wednesday. The stock traded as low as $29.14 and last traded at $29.47. 130,560 shares traded hands during mid-day trading, a decline of 58%…
Nuvectis Pharma (NASDAQ:NVCT) Shares Down 7.5% - Should You Sell?
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) fell 7.5% during mid-day trading on Wednesday. The stock traded as low as $21.53 and last traded at $21.2710. 28,119 shares were traded during mid-day trading, a decline of 84% from the average…
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Moderna, Inc. (MRNA) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 8:50 AM EDT Stéphane Bancel - CEO & Director David Berman - Chief Development Officer Courtney Breen - Bernstein…
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference 2026 September 23, 2026 5:55 AM EDT Richard Francis - President, CEO & Director Jason Gerberry - BofA Securities, Research Division BofA Securities, Research…
Cosmetics From Pakistan Breach Indian Market
CDSCO has warned consumers against using two unauthorised Pakistani whitening creams after finding excessive heavy metals and regulatory violations. India's CDSCO has issued a public health warning against Goree beauty cream and Chandni whitening…
CROSSJECT and BARDA align ZEPIZURE's Pediatric development plan with FDA including funding through 2030
CROSSJECT and BARDA have consolidated the clinical development plan for the pediatric indication of ZEPIZURE, in alignment with the FDA guidance $4.7 million in additional, non-dilutive funding, to cover the planned activities — total BARDA…
Homegrown air cargo titan Hactl celebrates 50-year journey
From fine cuisine at restaurants and fresh produce at supermarkets, to artistic masterpieces in museums and horses on the racetracks, many of these things we take for granted would have been out of reach if not for the work of an indispensable…
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX)
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial.
UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
UCB SA (UCBJY) Bank of America Global Healthcare Conference 2026 September 23, 2026 6:45 AM EDT Sandrine Dufour - Executive VP & CFO Charlie Haywood - BofA Securities, Research Division BofA Securities, Research Division Good morning, everyone.
Basecamp Research raises $140M to advance AI-designed therapeutics
Oversubscribed Series C led by S32 with backing from NVIDIA and others Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships The company has demonstrated strong…
Receive a Daily briefing on Pharma Industry News
Get Started